Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nova Eye Medical ( (AU:EYE) ) has issued an announcement.
Nova Eye Medical has reported record monthly sales in the U.S. for April 2026, surpassing March’s high, and lifted trailing twelve‑month group sales to US$22.8 million, up 26% year on year. Sales excluding China reached US$21.6 million, a 27% rise, underpinned by strong growth in direct markets and the rest of world, with the U.S. remaining the main driver.
On the back of this momentum and its first positive EBITDA from operations in Q3 FY26, the company has upgraded full‑year FY26 sales guidance excluding China to US$22–23 million. Management highlighted sustained demand in the fast‑growing U.S. interventional glaucoma market, where canaloplasty and stent‑free, tissue‑sparing procedures are gaining traction, supporting Nova Eye’s positioning in this segment.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company focused on advanced ophthalmic treatment devices for glaucoma. Its portfolio includes the iTrack Advance minimally invasive consumable device for restoring the eye’s natural outflow pathway in mild to moderate glaucoma, and the Molteno3 drainage implant for long-term intraocular pressure control in severe cases. The company sells globally via a distribution network, with sales headquarters and manufacturing in Fremont, California, and additional manufacturing in Dunedin, New Zealand.
Average Trading Volume: 263,423
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$35.61M
See more data about EYE stock on TipRanks’ Stock Analysis page.